Federal contractor · SAN DIEGO, CA

BIG EYE DIAGNOSTICS INC

No contract obligations recorded for BIG EYE DIAGNOSTICS INC in FY2026. Since FY2024: $599.6K.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
C3KTPAW1E1Z7
Small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 299.7KFY2024
  2. 300KFY2025

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for BIG EYE DIAGNOSTICS INC in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

BIG EYE DIAGNOSTICS INC received $0 in federal assistance in FY2026, on 3 actions (0 new awards), −100% vs FY2025.

Assistance · FY2026
$0
New awards
0
Actions
3
Since FY2022
$5.2M

Assistance by fiscal year

  1. 517.7KFY2022
  2. 921.5KFY2023
  3. 2.6MFY2024
  4. 1.2MFY2025
  5. 0FY2026

Largest awards

  1. ULTRASENSITIVE, HIGH-SPECIFICITY RAPID TEST TO SUPPORT THE END-GAME OF THE GLOBAL PROGRAM TO ELIMINATE LYMPHATIC FILARIASIS - PROJECT…$2M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Apr 15, 2022 – Jun 3, 2026· R44AI170131
  2. SUPPORTING WHO ONCHOCERCIASIS ELIMINATION PROGRAMS: PROGRESSING A HIGHLY SENSITIVE AND ULTRA-SPECIFIC RAPID DIAGNOSTIC TEST TO…$1.8M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Mar 16, 2023 – Aug 5, 2026· R44AI174495
  3. SUPPORTING WHO LYMPHATIC FILARIASIS ELIMINATION PROGRAMS: PROGRESSING A HIGHLY SENSITIVE AND SPECIFIC RAPID DIAGNOSTIC TEST FOR BRUGIA…$1.2M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Apr 25, 2024 – Feb 2, 2026· R44AI184015

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 6, 2026, loaded Oct 6, 2026 · FY2022–FY2026.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 1 market (agency × industry), FY2024–FY2026.

  1. ENEPRET INCORPORATED$599.5K−100% in FY2026
    LEXINGTON, KY · 100.0% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  2. VITRUVIAN BIO, LLC$600K
    BALTIMORE, MD · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  3. KEPHERA DIAGNOSTICS LLC$600K−100% in FY2026
    FRAMINGHAM, MA · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 6, 2026, loaded Oct 6, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 6, 2026, loaded Oct 6, 2026.